Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Dec;24(6):898-908.
doi: 10.1007/s11307-022-01739-9. Epub 2022 Jun 1.

Evaluating the Accuracy of FUCCI Cell Cycle In Vivo Fluorescent Imaging to Assess Tumor Proliferation in Preclinical Oncology Models

Yun Lu  1   2 , Adriana V F Massicano  1 , Carlos A Gallegos  3 , Katherine A Heinzman  3 , Sean W Parish  3 , Jason M Warram  4   5 , Anna G Sorace  6   7   8   9
Affiliations

Evaluating the Accuracy of FUCCI Cell Cycle In Vivo Fluorescent Imaging to Assess Tumor Proliferation in Preclinical Oncology Models

Yun Lu et al. Mol Imaging Biol. 2022 Dec.

Abstract

Purpose: The primary goal of this study is to evaluate the accuracy of the fluorescence ubiquitination cell cycle indicator (FUCCI) system with fluorescence in vivo imaging compared to 3'-deoxy-3'-[18F]fluorothymidine ([18F]-FLT) positron emission tomography (PET)/computed tomography (CT) and biological validation through histology. Imaging with [18F]-FLT PET/CT can be used to noninvasively assess cancer cell proliferation and has been utilized in both preclinical and clinical studies. However, a cost-effective and straightforward method for in vivo, cell cycle targeted cancer drug screening is needed prior to moving towards translational imaging methods such as PET/CT.

Procedures: In this study, fluorescent MDA-MB-231-FUCCI tumor growth was monitored weekly with caliper measurements and fluorescent imaging. Seven weeks post-injection, [18F]-FLT PET/CT was performed with a preclinical PET/CT, and tumors samples were harvested for histological analysis.

Results: RFP fluorescent signal significantly correlated with tumor volume (r = 0.8153, p < 0.0001). Cell proliferation measured by GFP fluorescent imaging was correlated with tumor growth rate (r = 0.6497, p < 0.001). Also, GFP+ cells and [18F]-FLT regions of high uptake were both spatially located in the tumor borders, indicating that the FUCCI-IVIS method may provide an accurate assessment of tumor heterogeneity of cell proliferation. The quantification of total GFP signal was correlated with the sum of tumor [18F]-FLT standard uptake value (SUV) (r = 0.5361, p = 0.0724). Finally, histological analysis confirmed viable cells in the tumor and the correlation of GFP + and Ki67 + cells (r = 0.6368, p = 0.0477).

Conclusion: Fluorescent imaging of the cell cycle provides a noninvasive accurate depiction of tumor progression and response to therapy, which may benefit in vivo testing of novel cancer therapeutics that target the cell cycle.

Keywords: Breast cancer; Cell cycle; Drug screening; Molecular imaging; Proliferative cell imaging; TNBC; [18F]-FLT PET/CT.

PubMed Disclaimer

References

    1. Diaz-Moralli S, Tarrado-Castellarnau M, Miranda A, Cascante M (2013) Targeting cell cycle regulation in cancer therapy. Pharmacol Ther 138(2):255–271 - PubMed
    1. Schwartz GK, Shah MA (2005) Targeting the cell cycle: a new approach to cancer therapy. J Clin Oncol Off J Am Soc Clin Oncol 23(36):9408–9421
    1. Sherr CJ, Bartek J (2017) Cell cycle–targeted cancer therapies. Annual Rev Cancer Biol 1(1):41–57
    1. Samadi P, Saki S, Dermani FK, Pourjafar M, Saidijam M (2018) Emerging ways to treat breast cancer: will promises be met? Cell Oncol (Dordr) 41(6):605–621
    1. McCann KE, Hurvitz SA, McAndrew N (2019) Advances in targeted therapies for triple-negative breast cancer. Drugs 79(11):1217–1230 - PubMed

Publication types

LinkOut - more resources